Participate in our company's research and development team.

Participate in our company's research and development team.

Participate in our company's research and development team.

1、 Basic Introduction of the Enterprise Hebei Luxide Biotechnology Co., Ltd. is located in the Industrial Development Zone of Shenzhou City, Hebei Province. It was established in 2013 with a registered capital of 10 million yuan and covers an area of over 60 acres. The company is adjacent to Shihuang Expressway and 307 National Highway to the south, Daguang Expressway and Beijing Kowloon Railway Line to the east, and Hengbao Road to the west, providing convenient transportation for the company's products to be shipped nationwide. Hebei Luke Xide Biotechnology Co., Ltd. is a high-tech private enterprise specializing in the research, production, and sales of probiotics. 2、 We plan to introduce expert talents. Our company is preparing to introduce Professor Jiang Sixu's student, postdoctoral Liu Rui. Currently, he is a researcher at Gyeonggi do University in South Korea and our company's full-time technical director. He is responsible for deepening research on the application of lactic acid bacteria with antibacterial and antiviral active ingredients in the field of animal husbandry. We are preparing to apply for a new type of non antibiotic feed additive to replace antibiotics. In response to the national call for a comprehensive ban on antibiotics on July 1, 2020, we are applying for a Class II new feed additive from the Ministry of Agriculture.

Study experience: 19809-19835 Bachelor's degree in Clinical Medicine, Department of Medicine, Taipei Medical College 19929-19945 Master's degree in Pediatric Medicine, Institute of Clinical Medicine, Kaohsiung Medical College 19949-19973 Master's degree in Public Health, School of Public Health, Hopkins University, USA 19979-20015 Doctoral degree in Public Health, Hopkins University, USA Work experience: 199612 Distinguished Professor, Hawaii State University, USA 199704 Distinguished Professor, Johns Hopkinson University, USA 199907 National Institutes of Health, 2001 Zhongshan Executive Director of the University Biological Education Center 200212 Deputy Director of the Institute of Traditional Chinese Medicine at Capital Medical University 200310 Doctoral Supervisor of the School of Life Sciences at Jinan University 200606 Counselor of the United Nations Educational, Scientific and Cultural Organization 200609 Senior Advisor of the World Health Organization Southern Europe Cooperation Center 2009 Executive Director of Neox Biopharmaceutical Technology Co., Ltd. 201312 Nobel Prize winner Dr. Murad Vice Dean of the Institute of Translational Sciences 201510 Founder of the Jingding Great Health Industrial Park 2016 Dr. Smoot, Chairman of Taiwan Asia Biochemical Technology Co., Ltd., won the Nobel Prize in January 2017, and Dean of the Academy of Translational Sciences. On January 2018, a representative of Japan Kyoyang Corporation banned the Targeted Brain Hypothermia Project. Dr. Lin Hengyi, a representative of Asia Pacific Medical Technology Development Co., Ltd., signed a cooperation agreement for the "China Giant Deer Medical Device Manufacturing and Distribution Base" project. The total planned investment for the project is 250 million yuan. To build a medical device manufacturing and distribution base in our park, this project mainly involves the construction of the first Aike membrane machine (i.e. an extracorporeal membrane lung care machine) with independent intellectual property rights produced in China, and the construction and production of the world's first three-in-one Aike membrane medical device that stabilizes blood pressure and cools the temperature. 2、 The 6D targeted tumor treatment bed has been developed in collaboration with Taiwan's Zion Biotechnology Co., Ltd. The 6D targeted tumor treatment bed obtained the medical device license number issued by the US Food and Drug Administration in June 2019. The 6D targeted tumor treatment bed, designed with a six degree of freedom axis and equipped with an intelligent robotic arm, enables the treatment bed that carries patients to treat them in an automated process, improving the accuracy of cancer treatment, and reducing the medical harm caused by the human body during radiation therapy. The total investment of this project is planned to be 100 million yuan, covering an area of 2500 square meters and a total construction area of 4000 square meters. After the production of the 6D targeted tumor treatment bed project, the first domestically produced 6D targeted tumor treatment bed will be manufactured and produced in our park, breaking through the long-standing technical barriers faced by Europe, America, and Japan in China. The 6D targeted tumor treatment bed in this project can accelerate the speed and accuracy of cancer treatment and examination, thereby reducing the proportion of deaths among Chinese people due to cancer and tumor diseases, and achieving significant social benefits.

1、 Hebei Ji Microbial Technology Co., Ltd. was established in 2002 and is headquartered in Baoding Prefecture, Fudi Prefecture, Beijing. Adhering to the business philosophy of "operation according to law, equality and voluntariness, safety and stability, and market operation", the company takes restoring ecological agriculture and creating green agriculture as its own responsibility, applies the national 863 project, and is committed to the research, development, production and promotion of microbial functional bacteria raw materials, agricultural microbial agents, and bio organic fertilizers with unique industry concepts and bacteria and fertilizer production processes. After extensive testing and application, our company's products have significant effects on disease prevention, yield increase, organic and taste improvement of crops, and can continuously improve and repair soil, promoting ecological restoration of farmland. Hebei Ji Microbial Technology Co., Ltd. is a high-tech company that integrates scientific research, development, production, and operation. It aims to create an annual production capacity of 20000 tons of high content liquid microbial inoculants and 10000 tons of high content soluble microbial bacterial powder and 100000 tons of bio organic fertilizer. The company relies on the technological advantages of Hebei Agricultural University, Hebei University, and Hebei Provincial Institute of Microbiology, and through modern enterprise operation models such as production research integration and joint entrepreneurship with technology experts, has attracted well-known microbiological and agricultural technology experts in the field of bioengineering research and application in China, We have established the "Jiwei R&D Center" and "Expert Service Team" to provide technical support for industry partners and users. Currently, we have developed and produced "Jiwei Active Phosphorus Potassium Microbial Seed Agent", "Baowei Guoyou 100 Microbial Seed Agent" The series of products such as Jiwei Duokang 58 Micro "Biological Bacterial Seed Agent and Its Microbial Phosphorus Potassium Fertilizer" have been promoted in more than 20 provinces, cities, and districts across the country, with a cumulative application area of nearly 200 million acres. Some of the products are also exported to countries such as Thailand, North Korea, Malaysia, and have been designated as experimental and export products by the "International Microbial Fertilizer Training Class" and "Semiarid Area Agricultural Production International Training Class", and have been awarded the "Top 10 Green, Pollution-free, and Environmentally Friendly Fertilizers in China" Multiple honors such as "Hebei Province Product Quality Inspection Qualified Enterprise". Hebei Ji Microbial Technology Co., Ltd. is based on the Agricultural Microbial Engineering Technology Research Center of Hebei Agricultural University, with advanced instruments and equipment, sufficient personnel, and a team with excellent quality, excellent business, mature technology, and combat effectiveness. The company pioneered the post-treatment processes of "centrifugal concentration+flash drying" and "centrifugal concentration+spray drying" of fermentation broth. The former can concentrate the bacteria content 20 times, while the latter can concentrate the bacteria content 100 times. This process has been used in the production of highly concentrated Bacillus thuringiensis powder since 2008, resulting in a higher number of live bacteria, lower water content, and longer shelf life for Bacillus thuringiensis products. It is the first in China and is currently the most advanced microbial agent post-treatment process in the world. As a result, the company has won the Hebei Province Science and Technology Progress Award for its production technology and process. The plan is to introduce experts with more academic prestige in improving soil microecology.

1. It is planned to introduce high-end technical talents in the industry, increase the investment in research and development, take innovative drug research, upgrading and transformation of traditional biochemical drug preparations, evaluation of consistency of quality and efficacy of generic drugs as the research and development direction, and take the development of high value-added products with independent intellectual property rights as the development goal to build a more integrated, systematic, mature and progressiveness drug comprehensive research and development platform. We will enhance the company's independent innovation capabilities and promote technological development cooperation with universities and research institutes. 2. We plan to introduce advanced high-end equipment and technologies from abroad, such as the introduction of world-class biotechnology (such as protein purification, bidirectional hydrolysis, chromatography separation, etc.), cooperation with Dr. Zhang Min's new research team from GLB Corporation in Japan, and advanced technologies such as industrialized fermentation and extraction technology, emulsification phenomenon treatment, and separation of various alkaloid components, to break through the bottleneck of industrialization.

1. It is planned to introduce high-end technical talents in the industry, increase the investment in research and development, take innovative drug research, upgrading and transformation of traditional biochemical drug preparations, evaluation of consistency of quality and efficacy of generic drugs as the research and development direction, and take the development of high value-added products with independent intellectual property rights as the development goal to build a more integrated, systematic, mature and progressiveness drug comprehensive research and development platform. We will enhance the company's independent innovation capabilities and promote technological development cooperation with universities and research institutes. 2. We plan to introduce advanced high-end equipment and technologies from abroad, such as the introduction of world-class biotechnology (such as protein purification, bidirectional hydrolysis, chromatography separation, etc.), cooperation with Dr. Zhang Min's new research team from GLB Corporation in Japan, and advanced technologies such as industrialized fermentation and extraction technology, emulsification phenomenon treatment, and separation of various alkaloid components, to break through the bottleneck of industrialization.

Introduce 1-3 foreign experts (majoring in biochemistry, biopharmaceuticals, and molecular biology), introduce high-level, refined, and cutting-edge talents from abroad to carry out scientific research work in the center, actively carry out research on the application of cutting-edge and upstream technologies, accelerate the transformation of independent innovation achievements, and promote the international development of the biopharmaceutical industry in our province.

It is to assist in applying for a visa to China